Original articleClinical outcomes of home parenteral nutrition patients using Taurolidine (cas 19388-87-5) as catheter lock: A long-term cohort study

Add time:08/13/2019    Source:sciencedirect.com

SummaryBackground & aimsCentral venous access device (CVAD)-related complications, such as central-line associated bloodstream infections (CLABSIs), CVAD-related venous thromboses (CRVTs) and –occlusions frequently occur in home parenteral nutrition (HPN) patients. A preventive strategy to decrease the incidence of CLABSIs is the use of CVAD lock solutions, such as 2% Taurolidine (cas 19388-87-5). The aim of this study was to evaluate long-term clinical outcomes of our HPN cohort while using taurolidine as lock solution. In addition, we explored risk factors associated with CVAD-related complications.

We also recommend Trading Suppliers and Manufacturers of Taurolidine (cas 19388-87-5). Pls Click Website Link as below: cas 19388-87-5 suppliers

Prev:Tinidazole (cas 19387-91-8) degradation assisted by solar radiation and iron-doped silica xerogels
Next:Cefazolin–gentamicin versus Taurolidine (cas 19388-87-5)–citrate for the prevention of infection in tunneled central catheters in hemodialysis patients: A quasi-experimental trial)